IKNA Ikena Oncology, Inc.

Nasdaq ikenaoncology.com


$ 8.69 $ 0.31 (3.69 %)    

Friday, 31-Oct-2025 15:59:54 EDT
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 8.71
$ 8.40
$ 7.52 x 1
$ 9.15 x 1
$ 8.34 - $ 8.71
$ 7.24 - $ 23.28
12,956
na
35.03M
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-24-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-12-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-14-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 inmagene-and-ikena-complete-merger-to-form-imagenebio-inc-begin-trading-on-nasdaq-under-ima-july-28-2025-secures-75m-financing-advances-phase-2b-trial-of-anti-ox40-antibody-img-007-for-atopic-dermatitis

The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker s...

 wedbush-maintains-neutral-on-ikena-oncology-lowers-price-target-to-23

Wedbush analyst David Nierengarten maintains Ikena Oncology (NASDAQ:IKNA) with a Neutral and lowers the price target from $2...

 ikena-oncology-q2-eps-006-beats-014-estimate

Ikena Oncology (NASDAQ:IKNA) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.14...

 ikena-oncology-q1-eps-018-beats-021-estimate

Ikena Oncology (NASDAQ:IKNA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21...

 ikena-and-inmagene-enter-merger-agreement-175m-to-support-img-007-development-includes-75m-private-placement-combined-company-imagenebio-to-target-atopic-dermatitis-expected-close-mid-2025-and-trade-on-nasdaq-under-the-ticker-ima

Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal ant...

 hc-wainwright--co-reiterates-buy-on-ikena-oncology-maintains-4-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $4 price t...

 ikena-oncology-q3-eps-021-beats-028-estimate

Ikena Oncology (NASDAQ:IKNA) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.28...

 hc-wainwright--co-reiterates-buy-on-ikena-oncology-maintains-4-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $4 price t...

 ikena-oncology-discontinues-ik-930-program-and-cuts-workforce-analyst-calls-it-disappointing

Ikena Oncology halts its IK-930 program after reviewing clinical data and resources, focusing on the novel MEK-RAF molecular gl...

 wedbush-downgrades-ikena-oncology-to-neutral-lowers-price-target-to-2

Wedbush analyst David Nierengarten downgrades Ikena Oncology (NASDAQ:IKNA) from Outperform to Neutral and lowers the price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION